These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 18849561

  • 21. Protein and energy metabolism response to the initial dose of infliximab in children with Crohn's disease.
    Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC.
    Inflamm Bowel Dis; 2007 Jun; 13(6):737-44. PubMed ID: 17243138
    [Abstract] [Full Text] [Related]

  • 22. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 23. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R, Stüber E, Häsler R, Nikolaus S, Kühbacher T, Hampe J, Bewig B, Schreiber S, Arlt A.
    J Crohns Colitis; 2012 May 01; 6(4):464-9. PubMed ID: 22398062
    [Abstract] [Full Text] [Related]

  • 24. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.
    J Crohns Colitis; 2011 Aug 01; 5(4):324-31. PubMed ID: 21683302
    [Abstract] [Full Text] [Related]

  • 25. BODY COMPOSITION IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS.
    Back IR, Marcon SS, Gaino NM, Vulcano DSB, Dorna MS, Sassaki LY.
    Arq Gastroenterol; 2017 Aug 01; 54(2):109-114. PubMed ID: 28198913
    [Abstract] [Full Text] [Related]

  • 26. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease.
    Uslu N, Usta Y, Saltik-Temizel IN, Demir H, Gürakan F, Ozen H, Yüce A.
    J Crohns Colitis; 2010 Feb 01; 4(1):106-9. PubMed ID: 21122492
    [Abstract] [Full Text] [Related]

  • 27. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Feb 01; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 28. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 29. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
    Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.
    Aliment Pharmacol Ther; 2010 Aug 14; 32(3):384-93. PubMed ID: 20491747
    [Abstract] [Full Text] [Related]

  • 30. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L.
    Dig Liver Dis; 2013 Mar 14; 45(3):258-62. PubMed ID: 23195667
    [Abstract] [Full Text] [Related]

  • 31. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.
    Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L.
    Inflamm Bowel Dis; 2009 Oct 14; 15(10):1476-84. PubMed ID: 19291781
    [Abstract] [Full Text] [Related]

  • 32. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 14; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 33. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M.
    Ann Rheum Dis; 2004 Dec 14; 63(12):1664-9. PubMed ID: 15297279
    [Abstract] [Full Text] [Related]

  • 34. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov 14; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 35. Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease.
    Wiskin AE, Wootton SA, Culliford DJ, Afzal NA, Jackson AA, Beattie RM.
    Clin Nutr; 2009 Dec 14; 28(6):652-6. PubMed ID: 19515463
    [Abstract] [Full Text] [Related]

  • 36. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.
    J Crohns Colitis; 2013 Oct 14; 7(9):736-43. PubMed ID: 23200919
    [Abstract] [Full Text] [Related]

  • 37. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW.
    Gut; 2007 Apr 14; 56(4):509-17. PubMed ID: 17082252
    [Abstract] [Full Text] [Related]

  • 38. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.
    Scand J Gastroenterol; 2012 May 14; 47(5):528-37. PubMed ID: 22356594
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A.
    J Crohns Colitis; 2010 Dec 14; 4(6):654-60. PubMed ID: 21122576
    [Abstract] [Full Text] [Related]

  • 40. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G, Putz R, Szabó D, Molnár K, Bodánszky H, Dezsofi A, Arató A.
    Orv Hetil; 2009 Oct 04; 150(40):1858-60. PubMed ID: 19789146
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.